[go: up one dir, main page]

WO2008101723A3 - Pharmaceutical composition containing a cholesterol absorption inhibitor - Google Patents

Pharmaceutical composition containing a cholesterol absorption inhibitor Download PDF

Info

Publication number
WO2008101723A3
WO2008101723A3 PCT/EP2008/001436 EP2008001436W WO2008101723A3 WO 2008101723 A3 WO2008101723 A3 WO 2008101723A3 EP 2008001436 W EP2008001436 W EP 2008001436W WO 2008101723 A3 WO2008101723 A3 WO 2008101723A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol absorption
absorption inhibitor
pharmaceutical composition
composition containing
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/001436
Other languages
French (fr)
Other versions
WO2008101723A2 (en
Inventor
Vesna Kroselj
Matej Smrkolj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRKA dd filed Critical KRKA dd
Priority to EP08715987A priority Critical patent/EP2120882A2/en
Publication of WO2008101723A2 publication Critical patent/WO2008101723A2/en
Publication of WO2008101723A3 publication Critical patent/WO2008101723A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising at least one cholesterol absorption inhibitor in amorphous form and at least one hydrophilic polymer, wherein the amorphous cholesterol absorption inhibitor is finely distributed within the hydrophilic polymer or at least one amorphous cholesterol absorption inhibitor and at least one hydrophilic polymer are dispersed onto a carrier.
PCT/EP2008/001436 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor Ceased WO2008101723A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08715987A EP2120882A2 (en) 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SIP-200700043 2007-02-23
SI200700043 2007-02-23

Publications (2)

Publication Number Publication Date
WO2008101723A2 WO2008101723A2 (en) 2008-08-28
WO2008101723A3 true WO2008101723A3 (en) 2008-11-27

Family

ID=39710560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001436 Ceased WO2008101723A2 (en) 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor

Country Status (2)

Country Link
EP (1) EP2120882A2 (en)
WO (1) WO2008101723A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CA2708159C (en) 2007-12-10 2016-01-26 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
TR200806302A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Solubility and stability enhancing pharmaceutical formulation.
TR200806300A2 (en) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Solubility enhancing pharmaceutical formulation
US20100209495A1 (en) * 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
ES2382773T3 (en) 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Ezetimibe compositions
TR200904500A2 (en) 2009-06-10 2009-10-21 Öner Levent Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals.
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2368543A1 (en) * 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
TR201009397A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
EP2566465A2 (en) * 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
TWI586380B (en) * 2013-12-18 2017-06-11 夢製藥公司 Pharmaceutical combination preparation comprising a hmg-coa reductase inhibitor and a cholesterol absorption inhibitor
KR20150079373A (en) 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
KR101834559B1 (en) 2015-02-27 2018-03-06 한미약품 주식회사 Solid composite formulation for oral administration comprising ezetimibe and rosuvastatin
CN105287513A (en) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 Ezetimibe medicine composition and preparation method thereof
CN105213342A (en) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 Ezetimibe sheet
CN105310993A (en) * 2015-11-17 2016-02-10 深圳信立泰药业股份有限公司 Pharmaceutical composition containing ezetimibe and preparation method of pharmaceutical composition
JP2017210455A (en) * 2016-05-27 2017-11-30 ニプロ株式会社 Ezetimibe-containing pharmaceutical composition
JP7115825B2 (en) * 2017-06-28 2022-08-09 日医工株式会社 Oral formulation containing ezetimibe and its manufacturing method
CN109718215A (en) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 A kind of Ezetimibe piece
CN115252565B (en) * 2022-05-30 2023-09-19 国药集团致君（深圳）制药有限公司 Ezetimibe tablet and preparation process and dissolution evaluation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008068762A2 (en) * 2006-12-07 2008-06-12 Noah Ben-Shalom Chitosan formulation for cholesterol reduction in humans

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008068762A2 (en) * 2006-12-07 2008-06-12 Noah Ben-Shalom Chitosan formulation for cholesterol reduction in humans

Also Published As

Publication number Publication date
WO2008101723A2 (en) 2008-08-28
EP2120882A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2008101723A3 (en) Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
ZA200809778B (en) Metallocene complex and polymerization catalyst composition containing the same
EP1995282A4 (en) Microparticle-containing viscoelastic layer, and pressure-sensitive adhesive tape or sheet
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
EP2053589A4 (en) Active matrix substrate, and display device having the substrate
WO2008089087A3 (en) Tablet-in-tablet compositions
WO2009106717A3 (en) Compounds with a guanidine structure and use thereof for as organopolysiloxane polycondensation catalysts
IL192925A0 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2008124682A3 (en) Oxygen-scavenging materials and articles formed therefrom
IL205406A0 (en) Alpha - (n - sulfonamido) acetamide compound, composition comprising the same and uses thereof
EP2274393A4 (en) Adhesive composition having non-tacky microspheres and sheets made therefrom
WO2010142795A3 (en) Inorganic carrier materials containing nitrogen
WO2008142569A3 (en) Topical compositions containing magaldrate
WO2005079827A3 (en) Antitumor agent
EP2245091A4 (en) Nanoparticle dispersion, compositions containing the same, and articles made therefrom
WO2006099232A3 (en) Antimicrobial pet wipes
WO2009047434A3 (en) Use of carriers as preservatives and pharmaceutical composition containing same
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof
GB0502787D0 (en) Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
WO2007098924A3 (en) Composition comprising an agent for stabilizing active substances in drinking water, effervescent mixture, method for the production thereof, and use thereof
WO2008148747A8 (en) Pdz domain modulators
WO2011006593A3 (en) Water-vapor permeable adhesive bandages
WO2009010298A8 (en) Paullone derivatives and its use
WO2007022734A8 (en) A composition for alleviating a hangover comprising hyaluronic acid and activated carbon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715987

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008715987

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE